---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291416761.md"
description: "Can-Fite Biopharma shares are trading higher after the company announced that its Phase 2a study evaluating Namodenoson in patients with advanced pancreatic ductal adenocarcinoma achieved its primary safety endpoint and demonstrated durable overall survival outcomes.."
datetime: "2026-07-01T12:00:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291416761.md)
  - [en](https://longbridge.com/en/news/291416761.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291416761.md)
---

# 

Can-Fite Biopharma shares are trading higher after the company announced that its Phase 2a study evaluating Namodenoson in patients with advanced pancreatic ductal adenocarcinoma achieved its primary safety endpoint and demonstrated durable overall survival outcomes..

### Related Stocks

- [CANF.US](https://longbridge.com/en/quote/CANF.US.md)

## Related News & Research

- [Mauna Kea says study lifts Cellvizio pancreatic cyst diagnostic accuracy to 96%](https://longbridge.com/en/news/294089520.md)
- [Is Medtronic’s (MDT) Pain-Portfolio Pivot Offsetting Quality Scrutiny From Its Pediatric Cannula Recall?](https://longbridge.com/en/news/294229928.md)
- [How the SEC is clearing the path for more companies to go public](https://longbridge.com/en/news/294409345.md)
- [Kura Oncology posts investor presentation on darlifarnib plus cabozantinib clinical update in renal cell carcinoma](https://longbridge.com/en/news/293940059.md)
- [Sei Investments Co. Decreases Stock Position in NetScout Systems, Inc. $NTCT](https://longbridge.com/en/news/294665454.md)